Qurient Co

Qurient Co P/CF

The P/CF (Price-to-Cash-Flow Ratio) of Qurient Co (115180.KQ) as of Oct 30, 2026 is -44.74. In the previous year, P/CF (Price-to-Cash-Flow Ratio) was -55.02 — a change of -18.68% (higher).

P/CF

-44.74

YoY

-18.68%

Last updated:

P/CF (Price-to-Cash-Flow Ratio) of Qurient Co is 2025 -44.74 . P/CF (Price-to-Cash-Flow Ratio) of Qurient Co was 2024 -55.02 . It decreases by -18.68% higher compared to the previous year.

The Qurient Co P/CF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/CF
Date
P/CF
Jan 1, 2018
-92.94 KRW
Jan 1, 2019
-53.45 KRW
Jan 1, 2020
-64.64 KRW
Jan 1, 2021
-52.64 KRW
Jan 1, 2022
-51.31 KRW
Jan 1, 2023
-58.40 KRW
Jan 1, 2024
-55.02 KRW
Jan 1, 2025
-44.74 KRW
The Qurient Co P/CF history
YEARP/CFYoY
-44.74-18.68%
-55.02-5.77%
-58.40+13.81%
-51.31-2.52%
-52.64-18.56%
-64.64+20.92%
-53.45-42.48%
-92.94-8.82%
-101.93-21.38%
-129.64-23.82%
-170.18-11.91%
-193.18—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Qurient Co Stock analysis

What does Qurient Co do? Qurient Co., Ltd. develops novel therapeutics with two main program phases. The development phase includes Q203 for drug-resistant tuberculosis, Q301 for atopic dermatitis, and Q701 for drug-resistant cancer and anti-cancer immunotherapy. The research phase focuses on five lipoxygenase (5LO) inhibitor asthma medicines and a cyclin dependent kinase 7 (CDK7) inhibitor cancer drug. The company generates revenue through these therapeutic programs, targeting pharmaceutical companies and healthcare providers seeking innovative treatments for resistant diseases and chronic conditions. Qurient's products are developed for specific medical needs, with Q203 addressing tuberculosis that resists standard drugs, Q301 treating skin inflammation conditions, and Q701 enhancing cancer immunotherapy. The research phase programs aim to advance asthma and cancer treatments through novel inhibitors. Pharmaceutical companies and healthcare providers purchase these therapies to address unmet medical needs in their markets. The company's revenue streams come from the development and potential commercialization of Q203, Q301, Q701, and the research phase programs. These programs target segments including tuberculosis treatment, dermatology, oncology, and respiratory diseases. Pharmaceutical firms and healthcare institutions are the primary buyers of Qurient's therapeutic solutions for drug-resistant conditions and advanced treatment options. Qurient Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Qurient Co stock

P/CF (Price-to-Cash-Flow Ratio) of Qurient Co is -44.74 in 2025.

P/CF (Price-to-Cash-Flow Ratio) of Qurient Co changed from -55.02 to -44.74, representing a -18.68% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of P/CF (Price-to-Cash-Flow Ratio) Qurient Co since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Cash-Flow ratio measures the stock price relative to operating cash flow per share. Unlike P/E, it is harder to manipulate as cash flow is less subject to accounting adjustments.

P/CF = Stock Price / Operating Cash Flow per Share

To evaluate P/CF (Price-to-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/CF (Price-to-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/CF (Price-to-Cash-Flow Ratio)'s Qurient Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Qurient Co

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Qurient Co